Top Ten most popular articles on this week!

pharmafile | July 5, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brenntag, Elizabeth Warren, HIV, Novartis, PrEP, cannabis, crispr, pharma 

The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to make chemical weapons to Syria. The announcement came as a relief to shareholders as shares in chemical distributor Brenntag plummeted after it was found they had send chemical weapon precursors to the war torn country.  

In the US, Senator Elizabeth Warren called on former FDA commissioner Scott Gottlieb to ‘immediately resign’ from the board of Pfizer as she slammed the ‘revolving door’ from the upper levels of governments to the boardrooms of business.

In other news the US government was awarded a new patent on PrEP while the British government called for more research into medicinal cannabis. For all this and more, check out this weeks’ top ten stories on

10. UK Government call for more research into medicinal cannabis

The British government has called for more research into cannabis-based medicinal products (CBMPs).

9. Janssen secures two positive CHMP opinions for Imbruvica label expansions

Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), it has been revealed.

8. ViiV’s Dovato approved in Europe as treatment option for HIV-1

ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen to approve Dovato (dolutegravir/lamivudine) as a treatment for HIV-1 infection.

7. FDA greenlights Pfizer biosimilar version of Genentech’s Avastin

Pfizer is celebrating the approval by the FDA of Zirabev, its biosimilar version of Genentech’s Avastin (bevacizumab), which is now approved in the US in all indications as its reference product, including metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer.

6. Medicines recalled after FMD alert

The MHRA has warned patients that batches of drugs for Parkinson’s, epilepsy and blood clots have been taken out of the legitimate supply chain during distribution and later reintroduced and given to patients.

5. Researchers use gene-editing tool CRISPR to cure mice of HIV

American scientists have been able to combine a new form of antiretroviral therapy (ART) with gene editing tool CRISPR/Cas9 to cure mice with HIV.

4. US Government awarded new patent on preventative HIV drugs PrEP

The Department of Health and Human Services (HHS) has been awarded a new patent on drugs that prevent HIV.

3. Elizabeth Warren calls on former FDA commissioner Scott Gottlieb to resign from board of Pfizer

Democrat Presidential candidate Elizabeth Warren has criticised Scott Gottlieb for joining Pfizer.

2. Pfizer’s Revatio flops in Phase 3 trial

American multinational Pfizer has said that their drug Revatio (Sildenafil Citrate) in combination with nitric oxide has failed to meet its primary endpoint in a Phase 3 trial.

1. Novartis says it did not send substances for chemical weapons to Syria

Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to Syria.

Related Content

SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy

Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its …

FDA relaxes blood donation regulations for MSM

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …

Latest content